ROS1 and non-small cell lung carcinoma: Genotyping was not routinely suggested for patients with resected ES‐NSCLC during 2003–2016, thus the current study was unable to answer whether pACT provided different survival advantages for patients with distinct actionable genetic alterations (e.g., EGFR mutations, ALK, or ROS1 fusions).